Value and Outcomes conducted a Q&A with past International Society for Pharmacoeconomoics and Outcomes Research president Louis Garrison on real-world evidence and health technology assessment.
Garrison was ISPOR’s president from July 2016-June 2017, but now serves as chair of the Past Presidents Council.
Below is an excerpt from the interview:
Value & Outcomes Spotlight: It has now been more than 10 years since Peter J. Neumann, ScD and you co-chaired an ISPOR task force on real-world data (RWD). There seems to be growing emphasis on the use real-world evidence (RWE) in the context of health technology assessment (HTA). Can you explain the sudden resurgence?
Lou Garrison: Our task force report was published in 2007, but our work began a couple of years before. So, ISPOR has been at this for well over 10 years, and has a lot of output and contributions from a number of task forces to show for it. As a scientific society, ISPOR has done a great deal to move this forward.
That first task force struggled with defining “real-world data” and with the distinction between RWD and RWE. In the end, we adopted an operational definition of “data used for decision-making that are not collected in conventional RCTs.” Even then—before “big data” became a buzzword — folks were aware that data are the raw materials and are shaped into insights and evidence for decision making, such as HTA. We have also seen the emergence of “data science” as a distinct academic discipline. Currently, we are increasingly seeing big data as an essential mechanism for generating RWE, which I interpret as “information”—an economic good.
To read the full Q&A session, click here.